Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference28 articles.
1. Trastuzumab-mechanism of action and use in clinical practice;Hudis;New Engl J Med,2007
2. Mechanisms of disease: angiogenesis and the management of breast cancer;Banerjee;Nat Clin Pract Oncol,2007
3. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer;Miller;J Clin Oncol,2005
4. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;New Engl J Med,2007
5. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO;Miles;J Clin Oncol,2008
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer;Acta Oncologica;2022-02-09
2. Sustainability Challenge of Eastern Europe—Historical Legacy, Belt and Road Initiative, Population Aging and Migration;Sustainability;2021-10-05
3. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France;BMC Cancer;2019-02-11
4. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer;Clinical and Translational Oncology;2017-08-07
5. Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer;Breast Cancer Research and Treatment;2017-07-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3